Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN (PARTITION)
NCT03549637 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 896
Last updated 2021-09-16
Summary
The links between low LDL-C levels and psychologic symptoms (psychotic disorders, mood disorders, aggressivity, suicidal risk, etc.) and cognitive deficits (mainly executing functioning) are debated. The PARTITION study aims at estimating the prevalence of hypobetalipoproteinemia (HBL), defined as a LDL-C level ≤ 0,50 g/L, in a psychiatric population.
Conditions
- Familial Hypobetalipoproteinemia
Interventions
- DIAGNOSTIC_TEST
-
Psychiatric population
Genetic and biological analysis of patients
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Principal Investigators
-
Marie GRALL-BRONNEC, Pr · Nantes University Hospital Nantes
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-22
- Primary Completion
- 2021-03-17
- Completion
- 2021-03-17
Countries
- France
Study Locations
More Related Trials
-
A Study of Olanzapine in Participants With Bipolar Disorder.
NCT07263191 ·Status: RECRUITING
-
Short Term Rescue Study of Olanzapine
NCT00186017 ·Status: COMPLETED ·Phase: PHASE4
-
An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients
NCT00520507 ·Status: COMPLETED ·Phase: PHASE4
-
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
NCT00716755 ·Status: COMPLETED ·Phase: NA
-
Olanzapine in Patients With Borderline Personality Disorder
NCT00091650 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
NCT00034580 ·Status: COMPLETED ·Phase: PHASE4
-
Optimisation of Antipsychotic Drug Use in Older People
NCT01454453 ·Status: TERMINATED ·Phase: PHASE4
-
Olanzapine Treatment of Patients With Bipolar I Disorder
NCT00510146 ·Status: COMPLETED ·Phase: PHASE3
-
Clozapine-related Immunodeficiency in Parkinsons Disease
NCT06634641 ·Status: RECRUITING ·Phase: PHASE4
-
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
NCT00632645 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
NCT02307396 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Post-Authorisation Safety Study of Asenapine (Sycrest)
NCT01734278 ·Status: COMPLETED
-
The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)
NCT03692182 ·Status: COMPLETED
-
Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)
NCT02287259 ·Status: COMPLETED ·Phase: PHASE4
-
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
NCT00320489 ·Status: COMPLETED ·Phase: PHASE3
-
Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
NCT00183612 ·Status: TERMINATED ·Phase: NA
-
Side Effects of Newer Antipsychotics in Older Adults
NCT00245206 ·Status: COMPLETED ·Phase: PHASE4
-
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
NCT00645099 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571 ·Status: COMPLETED ·Phase: PHASE4
-
Acute Olanzapine and Lipid Response
NCT04181385 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281 ·Status: COMPLETED ·Phase: PHASE3
-
Hematological Effects of Atypical Antipsychotics (AAPs) in a Geriatric Population: What is the Role of 5-HT2 Receptors
NCT06107322 ·Status: RECRUITING
-
Optimal Duration of Olanzapine Add-on Therapy in Major Depression
NCT00568672 ·Status: WITHDRAWN ·Phase: PHASE3
-
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
NCT00275301 ·Status: COMPLETED ·Phase: NA